KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Net Income: 2009-2025

Historic Net Income for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to -$27.1 million.

  • Neogenomics' Net Income fell 53.28% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.5 million, marking a year-over-year decrease of 45.98%. This contributed to the annual value of -$78.7 million for FY2024, which is 10.51% up from last year.
  • Neogenomics' Net Income amounted to -$27.1 million in Q3 2025, which was up 39.84% from -$45.1 million recorded in Q2 2025.
  • Neogenomics' 5-year Net Income high stood at $75.9 million for Q2 2021, and its period low was -$49.4 million during Q1 2022.
  • Moreover, its 3-year median value for Net Income was -$24.3 million (2023), whereas its average is -$24.1 million.
  • Within the past 5 years, the most significant YoY rise in Neogenomics' Net Income was 1,211.86% (2021), while the steepest drop was 895.78% (2021).
  • Over the past 5 years, Neogenomics' Net Income (Quarterly) stood at -$41.8 million in 2021, then skyrocketed by 45.67% to -$22.7 million in 2022, then spiked by 36.85% to -$14.3 million in 2023, then declined by 6.97% to -$15.3 million in 2024, then crashed by 53.28% to -$27.1 million in 2025.
  • Its Net Income stands at -$27.1 million for Q3 2025, versus -$45.1 million for Q2 2025 and -$25.9 million for Q1 2025.